
Pfizer Inc.
PFE 28.00 (1.76%) 0.49
Market cap
$159.59(B)Earnings date
Nov-03-2026Category
Sector
Health CareIndustry
PharmaceuticalsPfizer Inc. discovers develops manufactures markets distributes and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma PC1 and Pfizer Ignite. The company offers internal medicine products including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family Abrysvo Nimenrix FSME/IMMUN-TicoVac and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products such as Xeljanz Enbrel Cibinqo Litfulo Eucrisa and Velsipity; rare disease products for therapeutic areas comprising amyloidosis hemophilia and endocrine diseases under the Vyndaqel family Genotropin BeneFIX Xyntha Somavert Ngenla and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta Octagam and Panzyga brands. In addition the company offers oncology products comprising ADCs small molecules bispecific and other immunotherapies for the treatment of cancers including breast cancer genitourinary cancer and hematologic malignancies as well as melanoma gastrointestinal gynecological and lung cancer under the Ibrance Xtandi Padcev Adcetris Inlyta Lorbrena Bosulif Tukysa Braftovi Mektovi Orgovyx Elrexfio Tivdak and Talzenna brands. Further it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit Ruxience Zirabev Trazimera and Nivestym and other biosimilars; and sterile injectables such as Sulperazon Atgam Fragmin Solu Medrol Solu Cortef and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US Inc.; Merck KGaA; and BioNTech SE as well as a strategic collaboration with Boltz PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York New York.
EV: $223.21(B)
Total Equity: $85.49(B)
Debt/Equity: 0.74
Dividend/share: $1.7
Div. yield: 6.14%
P/E: 36.84
Forward P/E: 9.43
P/FCF: 14.51
P/S: 2.50
P/B: 1.87
EPS: $0.8
EPS (fwd): $3.0
FCF/share: $1.9
Revenue/share: $11.2
Book value/share: $14.9
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Margins: Gross | Op. | Net
74.7% | 24.6% | 6.8%
0.0%of Portfolio
My holdings
Day change
Total change
PEvaluation
CURRENT PRICE
$28
48% Undervalued
BEAR
$31
11%
BASE
$42
48%
BULL
$52
85%
Fair P/E
Margin of safety
EPS
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 2.9 | 3.0 | 3.1 | 25 |
| FY+2 | 2.5 | 2.9 | 3.2 | 25 |
| FY+3 | 2.0 | 2.5 | 2.9 | 19 |
| FY+4 | 1.8 | 2.3 | 2.9 | 12 |
| FY+5 | 1.9 | 2.4 | 3.1 | 12 |
Analyst Price Targets
CURRENT PRICE
$28
0% Undervalued
BEAR
$25
11%
BASE
$28
0%
BULL
$36
28%
Analyst Recommendations
Strong Buy2
Buy8
Hold16
Sell1
Strong Sell1
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
% Low Mid High | |
Terminal Growth Rate | |
% Low Mid High | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
% Low Mid High | |
| Discount Rate | |
Free cash flow estimates:
Y+1 est.
Y+2 est.0.00%
Y+3 est.0.00%
Y+4 est.0.00%
Y+5 est.0.00%
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
x Low Mid High | |
| Discount Rate | |
Free cash flow estimates:
Y+1 est.
Y+2 est.0.00%
Y+3 est.0.00%
Y+4 est.0.00%
Y+5 est.0.00%
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
First Stage Growth Rate | |
% Low Mid High | |
Final Growth Rate | |
% Low Mid High | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
% Low Mid High | |
Final P/E | |
x Low Mid High | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
% Low Mid High | |
Final Net Margin | |
% Low Mid High | |
Final P/E Ratio | |
x Low Mid High | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
Growth Rate | |
% Low Mid High | |
Graham Formula
| Earnings Per Share | |
EPS Growth (7-10 years) | |
% Low Mid High | |
| Government Bond Rate | |
